Peter Dolan

Mr. Dolan is Chairman of the Board of Trustees of Tufts University. He was elected Chair in 2013, having served on the Tufts Board since 2001. He is Chairman of the Board of the Partnership for A Healthier America and has served on that Board since 2010. He is also currently on the Board of Amplitude Health Care (healthcare SPAC). Previously, from 1988-2006, Mr. Dolan was at Bristol-Myers Squibb, eventually serving as Chairman and CEO, and as CEO. He joined Bristol-Myers Squibb from General Foods. After more than a decade leading the BMS Consumer Products, Nutritionals, and Medical Device businesses, he was named CEO in 2001 at age 45. As CEO, he led the acquisition of DuPont Pharmaceuticals, which brought Eliquis to the company, and by 2019, Eliquis was the second largest drug in global industry annual prescription drug revenue. In 2001, the successful investment in Imclone’s Erbitux successfully bolstered Bristol-Myers Squibb’s oncology business until the introductions of blockbusters Sprycel and Yervoy. Ushering the company into biologics, in 2004 Mr. Dolan licensed the immuno-oncology compound that became Yervoy, named the Biotech Discovery of the Decade in 2016 for extending survival in some of the hardest to treat forms of cancer. In 2006, he strengthened the company’s commitment to biologics with the largest capital investment in the company’s history to build the first Bristol-Myers Squibb biologics manufacturing facility.